How to buy Opthea Limited stock (Opthea Limited)

Opthea Limited is a biotechnology business based in the US. Opthea Limited shares (OPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.34 – an increase of 2.77% over the previous week. Opthea Limited employs 33 staff and has a trailing 12-month revenue of around $261,859.

Our top picks for where to buy Opthea stock

Buy Opthea Limited stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Opthea Limited stock price (NASDAQ: OPT)

Use our graph to track the performance of OPT stocks over time.

Opthea Limited shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$3.34
52-week range	$1.79 - $5.45
50-day moving average more info button	$4.00
200-day moving average more info button	$3.27
Wall St. target price	$12.17
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.76

Is it a good time to buy Opthea Limited stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Opthea Limited price performance over time

Historical closes compared with the close of $3.3401 from 2024-12-20

1 week (2024-12-13)	2.77%
1 month (2024-11-22)	5.70%
3 months (2024-09-20)	-15.84%
6 months (2024-06-21)	67.01%

1 year (2023-12-21)	29.96%
2 years (2022-12-21)	-35.72%
3 years (2021-12-21)	7.115
5 years (2019-12-18)	N/A

Opthea Limited financials

Revenue TTM	$261,859
Gross profit TTM	$218,449
Return on assets TTM	-83.43%
Return on equity TTM	-3383.08%
Profit margin	0%
Book value	$-0.07
Market Capitalization more info button	$507.2 million

TTM: trailing 12 months

Opthea Limited share dividends

We're not expecting Opthea Limited to pay a dividend over the next 12 months.

You may also wish to consider:

Have Opthea Limited's shares ever split?

Opthea Limited's shares were split on a 5:8 basis on 14 October 2020 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Opthea Limited shares – just the quantity. However, indirectly, the new 60% higher share price could have impacted the market appetite for Opthea Limited shares which in turn could have impacted Opthea Limited's share price.

Opthea Limited share price volatility

Over the last 12 months, Opthea Limited's shares have ranged in value from as little as $1.79 up to $5.45. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Opthea Limited's is 1.54. This would suggest that Opthea Limited's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Opthea Limited's beta into context you can compare it against those of similar companies.

• Kodiak Sciences (KOD.US): 2.251
• Regenxbio (RGNX.US): 1.232
• Kala Pharmaceuticals (KALA.US): -2.142

Opthea Limited overview

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia. .

Frequently asked questions

What percentage of Opthea Limited is owned by institutions?
Currently 3.573% of Opthea Limited shares are held by institutions. How many people work for Opthea Limited?
Latest data suggests 33 work at Opthea Limited. When does the fiscal year end for Opthea Limited?
Opthea Limited's fiscal year ends in June. Where is Opthea Limited based?
Opthea Limited's address is: 650 Chapel Street, South Yarra, VIC, Australia, 3141 What is Opthea Limited's ISIN number?
Opthea Limited's international securities identification number is: US68386J2087